Sangamo Biosciences Inc (SGMO)

[surf1944]

7:01AM Sangamo BioSci presents positive Phase 2 ZFP therapeutic data from SB-509 programs in diabetic neuropathy (SGMO) 3.99 : Co announced positive Phase 2 clinical data from its ZFP Therapeutic program to develop SB-509 as a treatment for diabetic neuropathy. Data from Sangamo's SB-509-601 and SB-509-701B Phase 2 clinical trials demonstrated that SB-509 treatment resulted in clinically beneficial improvements in subjects with moderate and severe DN as compared to placebo. The data, which were described in three oral presentations, provided direct histological evidence of SB-509's dual effect on both blood vessel and nerve growth and validated the strategy of the use of multi-endpoint disease severity criteria that have been established for enrollment into the co's ongoing Phase 2b trial in subjects with moderately severe DN.